SL-164

SL-164
Clinical data
ATC code
  • none
Identifiers
  • 5-chloro-3-(4-chloro-2-methylphenyl)-2-methylquinazolin-4-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H12Cl2N2O
Molar mass319.19 g·mol−1
3D model (JSmol)
  • ClC1=CC(C)=C(N2C(C)=NC3=CC=CC(Cl)=C3C2=O)C=C1
  • InChI=1S/C16H12Cl2N2O/c1-9-8-11(17)6-7-14(9)20-10(2)19-13-5-3-4-12(18)15(13)16(20)21/h3-8H,1-2H3
  • Key:KUIHLOHNUGOCTO-UHFFFAOYSA-N

SL-164, also known as dicloqualone or DCQ, is an analogue of methaqualone developed in the late 1960s by a team at Sumitomo.[1] SL-164 has similar sedative, hypnotic[2] and properties to the parent compound, but was never marketed for clinical use, due to higher risk of convulsions. Like other 4-substituted analogues, such as methylmethaqualone, SL-164 may cause seizures.[3]

References

  1. ^ US 3651230, "Compositions And Methods For Tranquilizing With Substituted 3-Phenyl-4-Quinazolinone Derivatives" 
  2. ^ Saito C, Sakai S, Yukawa Y, Yamamoto H, Takagi H (December 1969). "Pharmacological studies on 2-methyl-3(2'-methyl-4'-chlorophenyl)-5-chloro-4[H)-quinazolinone (SL-164)". Arzneimittel-Forschung. 19 (12): 1945–9. PMID 4985336.
  3. ^ Boltze KH, Dell HD, Lehwald H, Lorenz D, Rueberg-Schweer M (August 1963). "[Substituted 4-Quinazolinone Derivatives As Hypnotics]". Arzneimittel-Forschung (in German). 13: 688–701. PMID 14085923.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.